Date: {{$ActivityAssignDate}}

Dear Dr. {{ $doctorName }},


Subject: Investigating the New Strategies in Glycemic Management – OAD and Injectable Therapy Survey (INSIGHT)


Diabetes mellitus (DM) is a chronic progressive disorder characterized primarily by persistent hyperglycemia. According to the International Diabetes Federation, in 2021, around 537 million adults were diagnosed with DM world-wide. More than 90% of people with DM have type 2 DM(T2DM) which is characterized by chronic hyperglycemia and insulin resistance, contributing to the development of diabetes- related life- threatening complications. These complications can be prevented/attenuated by achieving adequate glycemic control following an appropriate non-pharmacological and pharmacological care plan.


The global landscape of type 2 diabetes mellitus (T2DM) management has evolved considerably over the last decade, especially in terms of the availability of new classes of antihyperglycemic agents (AHAs). Combination therapies with multiple modes of action are especially beneficial to achieve optimal glycemic control without provoking hypoglycaemia. The introduction of the triple FDC not only represents a pharmacological advancement but also addresses economic and accessibility challenges in the Indian healthcare landscape. Managing diabetes in India is compounded by the vast economic disparities that affect access to medications and healthcare services. This simplification can lead to improved adherence, especially in lower socioeconomic groups and in rural areas where healthcare access is limited. Such economic considerations are crucial in India, where the majority of the population incur out-of-pocket expenses for their healthcare services


This multicentre survey is planned to assess the role of triple fixed dose combinations in improving diabetes outcomes.


We invite you to participate in this survey. On acceptance, you will need to fill the survey questionnaire form provided.


We would encourage you to carefully fill all available information to the fullest in the questionnaire.


If you agree to participate in the said survey, we would request you to sign and return the enclosed reply along with your visiting card for accuracy of records.

Yours truly,

Ms. SEEMA SAMANT

Sun Pharma Laboratories Limited

Sun House, 201/B1, Western Express Highway,

Goregaon (East), Mumbai,

Maharashtra (India) – 400 063